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Abstract
Background: Human telomerase reverse transcriptase (hTERT) is a key component for synthesis
and maintenance of telomeres on chromosome ends and is required for the continued proliferation
of cells. Estimation of hTERT expression therefore has broad relevance in oncology and stem cell
research. Several splicing variants of hTERT have been described whose regulated expression
contributes to the control of telomerase activity. Knowledge of the different hTERT mRNA
isoforms and the ability to distinguish between them is an important issue when evaluating
telomerase expression.
Results: By establishing cDNA-clone panels from lung and colon tissues, we could map hTERT
clones individually for differences in DNA sequence. This made possible the identification of novel
alternatively spliced sites as well as analysis of their frequency and mutual correlation in mRNA
isoforms. Ten different alternatively spliced sites were detected, of which six were novel sites
resulting from alternative splicing of intron 2 or 14. The majority of hTERT cDNA clones from
normal and tumour lung and colon tissues encoded truncated proteins ending close after exon 2
or 6.
Conclusion: The increased complexity in telomerase expression revealed here has implications
for our understanding of telomerase regulation and for the choice of suitable methods for
addressing hTERT expression.
Background
The ends of eukaryotic chromosomes are usually capped
by telomeres which consist of repeated copies of a short
DNA sequence and several associated proteins [reviewed
in [1]]. The telomeres protect the chromosomes from
damage and degradation and from being fused together
by DNA repair mechanisms and are essential for genomic
integrity and cell viability. Since the conventional DNA
replication process is unable to completely synthesize
chromosome ends, proliferating cells lacking de novo syn-
thesis of telomeric DNA will eventually lose their telom-
eres and enter a growth-arrest state called replicative
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cells is ensured by the telomerase enzyme which main-
tains and synthesizes telomeric repeats on to chromo-
some ends [2,3]. In humans, telomerase activity has been
detected in many highly proliferative cells and tissues,
such as early stage embryos, reproductive tissues in testis
and ovary, stem cells, fibroblasts and activated lym-
phocytes [reviewed in [4]]. Most somatic tissues contain
undetectable levels of telomerase activity, but restoration
of telomerase activity is required for immortalization and
continued growth of cancer cells. Thus, regulation of tel-
omerase activity has important implications for many
developmental processes including cell proliferation, dif-
ferentiation, ageing and tumorigenesis.
The human telomerase holoenzyme is composed of two
core subunits, the telomerase RNA component hTERC [5],
which contains a template for telomere elongation, and
the telomerase reverse transcriptase catalytic subunit
hTERT [6-9]. While hTERC is widely expressed in human
tissues irrespective of telomerase status, the expression of
normal full-length hTERT correlates well with telomerase
activity and seems to be the rate-limiting factor for telom-
erase activity in human cells [7,8,10-13]. The hTERT gene
consists of 16 exons and spans ~37 kb of genomic DNA,
of which ~33 kb is intronic sequences and the remaining
~4 kb corresponds to the hTERT mRNA transcript [14].
Since processing of hTERT pre-mRNA also yields non-
functional alternatively spliced products, the correlation
between hTERT gene expression and telomerase activity is
complicated. To date, seven alternatively spliced sites
(ASPSs) in the hTERT mRNA have been described
[9,14,15]. Two ASPSs, α-deletion and γ-deletion, result
from in-frame deletions of exonic sequences in exon 6
and 11, respectively. The α-deletion isoform appear to be
a dominant inhibitor of telomerase activity when over-
expressed [16,17]. The remaining ASPSs represent exonic
deletions and/or insertion of intronic sequences that
cause frame shift and premature termination of the open
reading frame (ORF). Alternative splicing of hTERT has
implications for the regulation of telomerase activity
[10,18-20]. In particular, telomerase is down-regulated in
many tissues by a shift to β-deletion splicing mode, in
which exons 7 and 8 are deleted. Alternative splicing rec-
onciles many of the inconsistencies observed between
hTERT mRNA levels and lack of telomerase activity, but
telomerase-negative cells frequently contain hTERT
mRNA of which a fraction apparently is normal full-
length [11,13,21,22]. It has been suggested that this may
be due to downstream regulatory mechanisms, such as
inhibitory factors or post-translational modification of
the hTERT protein. It is also possible that the putative full-
length hTERT mRNA in such cases contained unknown
ASPSs, which consequently were not screened for. Here
we report the characterization of six novel hTERT ASPSs
detected in primary tissues from lung and colon that may
be important for the regulation of telomerase activity in
human cells.
Results
Characterization of hTERT ASPSs
To identify novel hTERT ASPSs and splice patterns, a sys-
tematic search was set up by establishing panels of cDNA
plasmid clones from five different tissues: lung tumour
and adjacent tissue, colon tumour, K562 and HL60 cell
lines. The cDNA clones were generated by RT-PCR using
two primers (p1255 and m3652; Table 1) that produce a
2409-bp fragment from normal full-length hTERT mRNA,
encompassing the positions of intron 2 to 15 (Fig. 1A). A
total of 134 cDNA clones were analysed individually by
screening with a panel of primer pairs (Table 1) covering
different sub-regions of the hTERT cDNA. Clones that
contained insertions and/or deletions compared to the
normal full-length isoform were analysed by DNA
sequencing. The screening detected ten different hTERT
ASPSs in addition to the normal full-length isoform (Fig.
1B) and six of these have not been described earlier. The
donor and acceptor splice sequences used to produce the
different ASPSs conform to the GT-AG consensus for
intron splicing in eukaryotes [23].
Three novel ASPSs were found that involve insertion of
sequences from intron 2. The ASPS named Ins-i2 [1–349]
(see Figure 1 for description of the naming convention
used) has inserted the first 349 nucleotides of intron 2 and
results from the use of an alternative 5'-splice donor
sequence within intron 2 (Fig. 1D). The same splice site
has also been used to produce the ASPS Ins-i2 [182–349].
But in this ASPS an additional splicing event has removed
the first 181 nucleotides of intron 2 by use of the normal
Table 1: Primer pairs used for hTERT PCR analysis
Target 1) Primer pair 2) Ampl. (bp)
intron 2–15 p1255: ggaattctggagctgcttgggaacca
m3652: cgtctagagccggacactcagccttca
2409
intron 2 p1252: tgtttctggagctgcttgggaacca
m1725: tcatcagccagtgcaggaacttg
474
intron 2–3 p1509: tggggctccaggcacaacgaa
m1955: cttggggatgaagcggagtct
447
intron 4 p1870: tgcgggagctgtcggaagcagag
m2170: cgcacacgcagcacgaaggt
301
intron 5–9 p2182: cgccgcctgagctgtactttgtc
m2681: gctctagatccaccaaacgcaggagca
507
intron 10–13 p2660: gctgctcctgcgtttggtggatgat
m3164: ggggttcttccaaacttgctgatg
505
intron 14–15 p3194: ggcctccctctgctactccatcct
m3652: cgtctagagccggacactcagccttca
466
intron 14–15 p3194: ggcctccctctgctactccatcct
m3925: gggcacacctttggtcactcc
732
1) Positions of indicated introns are included in PCR product. 2) Primer 
sequences are from 5' to 3'. p, forward primer; m, reverse primer.Page 2 of 10
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Genomic organization and ASPSs of the hTERT geneFigure 1
Genomic organization and ASPSs of the hTERT gene. (A) Exon/intron organization of the hTERT gene assembled from 
[Genbank:AF128893] and [GenBank:AF128894] [14]. Exons are shown as black boxes with numbering above. Start/Stop indi-
cates the beginning and end of the ORF. (B) Schematic drawing of hTERT mRNA ASPSs. Exons are shown as open boxes with 
numbering inside. Black boxes represent intronic sequences and are cross-hatched to indicate uncharacterised 5' or 3' splice 
site. The ORF is indicated below each ASPS by arrows. The hTERT ASPSs have been assigned descriptive names: Ins-i, insertion 
of intronic sequence; Del-e, deletion of exonic sequence; followed by intron/exon number and a range of nucleotides in brack-
ets when the insertion/deletion involves part of an intron/exon, respectively. (C) Formerly used designations: *[9], **[14], 
***[15]. (D) Sequence of donor and acceptor splice sites. Unspliced sequence is boxed. Range of spliced nucleotides numbered 
from the first nucleotide of each intron is shown above the sequence.
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GTGCCTGCAG .//. GGGTTGGCTGGTTACCTATA CTCGTTTAAGIns-i2[1-349]
GAGCCCAG .//. TTTGCATA.//.GCCTGCAG .//. GGGTTGGCGTGAGGAG CTGTCCAG GTTACCTA CGTTTAAGIns-i2[182-349]
Ins-i14[623-705] GAACGCAG CCGAAGAA.//.CGTCGGGT GGATGTCGGTATGTGC.//.TGGAGAAG GTGGGCAG.//.TCCCCCAG
Ins-i14[623-703] GAACGCAG CCGAAGAA.//.ACCGTCGG GGATGTCGGTATGTGC.//.TGGAGAAG GTGTGGGC.//.TCCCCCAG
Ins-i2[?-5273] GGAGCATGAC GGGTTGGCTGGTGAGCCATG.//.CTCGTTTAAG
Intron 2 350-8616
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BMC Molecular Biology 2006, 7:26 http://www.biomedcentral.com/1471-2199/7/265'-splice donor sequence and an alternative 3'-splice
acceptor sequence, leaving nucleotides 182–349 of intron
2 in the spliced product. The third ASPS involving intron
2, Ins-i2 [?–5273], results from the use of an alternative 5'-
splice donor sequence within intron 2, but we were not
able to characterize this ASPS completely. The RT-PCR
cDNA clones containing this ASPS result from internal
priming of the 14 3'-most nucleotides of the p1255
primer at position 5212–5225 of intron 2.  Consequently,
the sequences located 5' to nucleotide position 5212 of
intron 2 were missing from the clones. In principle, the
insertion could involve nucleotides 1–5273 of intron 2, or
other sub-regions further upstream may be spliced out.
The complete lack of Ins-i2 [?–5273] clones produced by
normal priming in exon 2 indicates that it either lacks part
of exon 2, or is too long to be efficiently amplified by PCR
together with other isoforms.
The remaining novel ASPSs contain inserted sequences
from intron 14. The ASPSs Ins-i14 [623–705] and Ins-i14
[623–703] both result from a double splicing event in
intron 14, which leaves an internal fragment of intron 14
(nucleotides 623–705 and 623–703, respectively) in the
spliced product. In addition, two cDNA clones contained
an unspliced intron 14.
The screening also detected several ASPSs that have
already been described in the literature (see Figure 1B–C).
These include Ins-i4 [1–38], Del-e6 [1–36], Del-e7e8 and
Ins-i14 [623–781] [9]. Two ASPSs that have been
described by others were not observed among the 134
cDNA clones. These include Del-e11 [15] and Ins-i11 [1-
?] [9] (see Figure 1B–C). No ASPSs were found that are
associated with alternative splicing of intron 3, 5, 9, 10,
11, 12, 13 or 15. Since the primers used to generate RT-
PCR cDNA clones anneal in exon 2 and 16 respectively,
potential ASPSs involving intron 1 or deletions in exon 1,
2 or 16 could not be addressed in this screening, including
Ins-i14 [1–600]/Del-e15e16 [1–492] [14].
Quantitative analysis of RT-PCR cDNA-clone panels
Assuming that the RT-PCR cDNA clones represent a ran-
dom selection of mRNA isoforms present in the sample
analysed, statistical analyses were employed to address
quantitative and correlative relationships. The quantita-
tive data obtained by this approach relates to the percent-
age-wise distribution of ASPSs within a sample and does
not address absolute expression levels. Figure 2 (black
bars) summarizes the ASPSs found in RT-PCR cDNA
clones from four different samples. Distinct differences
were observed in splice pattern between the samples.
Frequency of hTERT mRNA ASPSs in RT-PCR cDNA clonesigur  2
Frequency of hTERT mRNA ASPSs in RT-PCR cDNA clones. The tissue of origin is indicated above the graph with 
number of analysed clones in brackets. Black bars show the percentage of clones containing the indicated ASPS. The fraction of 
these for which the 5'-splice donor site is continuous with the ORF (not masked by other ASPSs further upstream that termi-
nate the ORF) is shown by an adjacent cross-hatched bar.
0 20 40 60 80
Ins-i2[1-349]
Ins-i2[182-349]
Ins-i2[?-5273]
Ins-i4[1-38]
Del-e6[1-36]
Del-e7e8
Del-e11
Ins-i14[623-781]
Ins-i14[623-705]
Ins-i14[623-703]
Ins-i14
Full-length
0 20 40 60 80 0 20 40 60 80 0 20 40 60 80
Lung adj. tissue (n=31)
% of clones containing ASPS
% of clones containing ASPS being continuous with the ORF
Lung tumour (n=28) Colon tumour (n=32) K562 cell line (n=21)Page 4 of 10
(page number not for citation purposes)
BMC Molecular Biology 2006, 7:26 http://www.biomedcentral.com/1471-2199/7/26Besides the normal full-length isoform, Del-e7e8 was the
only ASPS detected in all samples and was found in ~80%
of clones from lung tumour and adjacent tissue, in 43%
from K562 and in 16% from colon tumour. Normal full-
length clones were found at moderate levels in colon and
lung tumour/adjacent tissue (14–22%) and at a noticea-
bly higher level in clones from K562 (47%). Several ASPSs
were found only in clones from lung adjacent tissue.
These include Ins-i2 [1–349] (32%), Ins-i14 [623–705]
(19%) and Ins-i14 (6%). Other ASPSs were found only in
clones from tumour tissues and include Ins-i4 [1–38] (5–
47%), Del-e6 [1–36] (0–53%) and Ins-i14 [623–781] (0–
25%). The ASPS Ins-i2 [?–5273] was present in a moder-
ate number of clones from lung adjacent tissue (6%) and
at considerably higher levels in lung and colon tumour
samples (25% and 38% respectively).
Since many ASPSs result in frame shift and premature ter-
mination of the ORF, the expected frequency of a particu-
lar protein isoform does not depend on the frequency of
the corresponding ASPS in mRNA only, but also on the
presence of additional ASPSs located further upstream in
the same mRNAs. To address this question, the cDNA
clones were mapped individually for the presence of alter-
native 5'-splice donor sites being continuous with the
main ORF (Fig. 2, cross-hatched bars). As may be
expected, the probability of a particular ASPS being
expressed at the protein level depends on its position on
the 5' to 3' axis. ASPSs involving intron 2 will always be
continuous with the main ORF, while those involving
intron 14 have a low probability of becoming part of a
protein. Table 2 shows a statistical analysis of correlation
computed on all cDNA clones. No strict correlation is
apparent between any pair of ASPSs, but two groups show
a significant level of co-occurrence. One group consists of
Ins-i2 [1–349] and Ins-i14 [623–705]. The other group
consists of Ins-i2 [?–5273], Ins-i4 [1–38], Del-e6 [1–36]
and Ins-i14 [623–781]. The groups correspond to the dis-
tribution of these ASPSs in normal and tumour tissues,
respectively.
Quantitative analysis of cDNA samples
To consolidate the data obtained by screening of RT-PCR
cDNA clones, five lung normal/adjacent tissue cDNA sam-
ples and seven colon tumour/adjacent tissue cDNA sam-
ples were screened by PCR using primer pairs (Table 1)
covering smaller sub-regions of hTERT. The results (Table
3) confirmed the presence of most ASPSs detected in RT-
PCR cDNA clones. The exception was the ASPS Ins-i14
which was not detected in any of the samples. Ins-i14 con-
tains a 781-bp insert and is probably subject to negative
selection when co-amplified with considerably shorter
products. The ASPS Ins-i14 [1–600]/Del-e15e16 [1–492],
which could not be addressed in the analysis of clones,
was not detected in any of the samples. Several ASPSs were
detected in tissues for which there are no corresponding
RT-PCR cDNA clones (see Figure 2). These include Ins-i2
[1–349], Del-e11, Ins-i14 [623–705] and Ins-i14 [623–
703] in both lung and colon tumour samples and Ins-i14
[623–781] in lung tumour/adjacent tissues. In addition,
two lung adjacent tissue samples contained the ASPSs Ins-
i4 [1–38] and Del-e6 [1–36]. Apparently, many ASPSs are
more widely expressed than identified by analysis of RT-
PCR cDNA clones. This may have several explanations.
The different samples used may have different splice pat-
terns (collected from different parts of organ, genetic var-
iation between donors, etc.) and/or the number of mRNA
molecules successfully amplified for generation of RT-
PCR cDNA clones was low. In addition, statistical sam-
pling errors were expected since the number of clones ana-
lysed is limited.
To estimate the quantitative error resulting from co-
amplification of PCR products of different sizes, the
change in percentages from 35 to 55 cycles of PCR was cal-
culated for individual samples and averaged (Table 3,
lower section). Apparently, ASPSs containing long inser-
tions are underestimated, while those having long dele-
tions are overestimated. The most notable case is
represented by Del-e11. The PCR product for Del-e11 is
316 bp compared to 505 for normal full-length. The per-
Table 2: Statistical correlation between hTERT ASPSs 1)
Ins-i2 [1–349] Ins-i2 [182–349] Ins-i2 [?–5273] Ins-i4 [1–38] Del-e6 [1–36] Del-e7e8
Ins-i4 [1–38] -0.12 -0.04 0.51
Del-e6 [1–36] -0.14 -0.04 0.32 0.34
Del-e7e8 0.28 -0.09 -0.03 -0.22 -0.10
Ins-i14 [623–781] -0.08 -0.02 0.42 0.44 0.30 -0.12
Ins-i14 [623–705] 0.63 -0.02 -0.09 -0.09 -0.10 0.14
Ins-i14 [623–703] -0.02 -0.01 -0.04 -0.04 -0.04 -0.09
Ins-i14 -0.03 -0.01 -0.05 -0.05 -0.06 0.12
1) Correlation coefficient calculated according to the formula: ρX, Y = cov(X, Y)/(σX·σY), where σx2 = Σ(Xi-µx)2/n, σy2 = Σ(Yi-µy)2/n (ρ; correlation 
coefficient, cov; co-variance, σ; standard deviation). The correlation coefficient is a number between -1 and 1: -1, mutually exclusive (all clones 
contain one or the other); 0, random distribution or both not present; 1, always occur together (independently of frequency).Page 5 of 10
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Table 3: PCR analysis of hTERT ASPSs in lung and colon tumour/adjacent tissue cDNA samples
Tissue Sample 1) Ins-i2 
[1–349]
Ins-i2 
[182–349]
Ins-i2 
[?–5273]
Ins-i4 
[1–38]
Del-e6 
[1–36]
Del- e7e8 Del-e11 Ins-i14 
[623–781]
Ins-i14 
[623–705]
Ins-i14 
[623–703]
α-tub 2)
Lung A 25.2 0.0 *7.3 5.6 7.3 71.5 0.0 8.5 0.0 0.0 77.1
Adjacent B N N N 0.0 0.0 99.9 0.0 0.0 0.0 0.0 70.6
C 0.0 0.0 0.0 0.0 0.0 0.0 0.0 47.5 0.0 0.0 61.9
D N N N 0.0 0.0 *100.0 N 0.0 0.0 0.0 62.5
E 0.0 0.0 0.0 100.0 100.0 100.0 N *51.3 0.0 0.0 61.1
Lung A 14.1 *0.5 13.3 1.8 2.9 39.5 0.0 1.4 0.4 *0.3 73.2
Tumour B 58.1 0.0 0.0 0.0 0.0 54.4 0.0 31.7 9.7 0.0 69.9
C 10.7 0.0 9.1 5.4 *1.8 76.9 *12.7 10.6 *0.3 0.0 73.2
D 0.0 0.0 0.0 0.0 0.0 76.7 0.0 18.5 0.0 0.0 79.3
E 7.0 *0.1 *42.8 6.3 6.2 82.6 5.4 8.5 0.8 0.9 68.4
Colon A 0.0 0.0 0.0 *24.2 14.8 75.3 0.0 0.0 0.0 *2.9 53.7
Adjacent B 0.0 0.0 0.0 0.0 8.8 64.5 0.0 *3.6 0.0 0.0 64.4
C 0.0 0.0 0.0 0.0 *4.7 65.7 0.0 10.2 0.0 0.0 55.9
D 0.0 0.0 0.0 0.0 0.0 53.4 0.0 2.7 0.0 0.0 45.6
E 0.0 0.0 0.0 0.0 0.0 81.0 0.0 *0.3 0.0 7.3 54.4
F 0.0 *100.0 0.0 N 0.0 57.4 0.0 0.0 0.0 0.0 82.4
G *0.1 *0.4 50.0 20.4 7.3 57.1 *0.6 3.1 0.0 0.0 88.9
Colon A 0.0 0.0 *100.0 0.0 0.0 69.7 0.0 0.0 0.0 0.0 57.3
Tumour B 29.2 0.0 0.0 19.6 22.3 63.2 0.0 16.6 0.0 *2.0 70.2
C 0.0 0.0 0.0 0.0 0.0 76.6 0.0 40.2 0.0 0.0 67.8
D 0.0 0.0 0.0 0.0 0.0 *54.1 0.0 13.2 0.0 0.0 68.3
E *6.2 0.0 0.0 8.8 0.0 81.5 0.0 8.0 0.0 0.0 60.1
F 2.5 0.0 20.2 22.7 7.1 58.1 0.4 3.9 0.7 0.7 91.7
G 0.0 0.0 94.9 4.2 5.3 53.2 0.0 4.5 0.5 0.7 90.8
Pooled 3) Tissue hTERT 4)sum total
PCR x35 Lung adjacent 25.1 0.0 0.0 11.1 17.9 61.9 0.0 13.6 0.0 0.0 1.0
Lung tumour 11.9 0.0 8.8 3.3 3.2 56.3 1.9 5.5 0.6 0.2 14.2
Colon adjacent 0.0 0.0 37.6 8.0 5.1 64.5 0.0 3.0 0.0 0.7 1.8
Colon tumour 6.7 0.0 69.6 6.4 5.3 55.0 0.2 4.8 0.6 0.7 1.5
Extrapolated
∆ 55/35 5) 0.55 - 2.22 1.71 2.02 1.11 5.29 0.76 1.03 1.06
Ampl. rate 6) 0.970 - 1.041 1.027 1.036 1.005 1.087 0.986 1.002 1.003
PCR start 7) Lung adjacent 72.0 - 0.0 4.3 5.2 51.8 0.0 22.0 0.0 0.0
Lung tumour 34.1 - 2.2 1.3 0.9 47.1 0.1 8.9 0.6 0.2
Colon adjacent 0.0 - 9.3 3.1 1.5 53.9 0.0 4.9 0.0 0.7
Colon tumour 19.2 - 17.2 2.5 1.5 46.1 0.0 7.8 0.5 0.6
1) Values are percentage ASPS of the total hTERT PCR products produced in each respective PCR reaction. ASPS products detected after 55 cycles of PCR only are denoted with an asterisk; 
remaining values are from 35 cycles of PCR. N; no PCR products (including normal full-length) detected after 35 or 55 cycles of PCR. 2)α-tubulin values are percentage of primer incorporated in 
product after 35 cycles of PCR. 3) For calculation of pooled data the samples were normalized to α-tubulin levels and PCR products produced after 35 cycles of PCR were combined before 
calculation of percentages (group of samples treated as one sample). 4) Sum totals (relative values) of all hTERT PCR products produced for a given tissue calculated from normalized values. 5) 
Average change in percentages from 35 to 55 cycles of PCR computed from individual samples; the number is a factor where 1 means no change. 6) Amplification rate per cycle compared to 
normal full-length product calculated by taking the 20th root of ∆. 7) Estimation of ASPS percentages by extrapolation of data from 35 cycles of PCR using the formula: (ASPS %)/(Ampl. rate)35.
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of PCR, which implies an amplification rate of 1.087 per
cycle compared to normal full-length. Extrapolation of
quantitative data back to PCR cycle 0 (Table 3, lower sec-
tion) resulted in Del-e11 percentages close to zero. Two
ASPSs, Ins-i4 [1–38] and Del-e6 [1–36], appeared to be
over-amplified although they differ little in size from nor-
mal full-length. The interpretation of quantitative data for
Ins-i2 [?–5273] requires special consideration. Similar to
the situation for generating cDNA clones (see above), the
PCR product for Ins-i2 [?–5273] is produced by internal
priming of the 14 3'-most nucleotides of the p1252
primer within intron 2 at position 5212–5225. The result-
ing PCR product is shortened by 325 bp compared to nor-
mal full-length and is over-amplified with an
amplification rate of 1.041. On the other hand, the melt-
ing temperature (Tm) for the initial pairing in intron 2 is
~42.5°C, which is 15.5°C below the hybridization tem-
perature used in PCR. Thus the quantitative data (extrap-
olated in particular) presented for Ins-i2 [?–5273] is most
likely underestimated by a considerable amount.
It was apparent from the PCR analysis that cDNA samples
from lung tumour yielded more hTERT PCR products
compared to the other tissues. To provide a rough esti-
mate of these differences, all hTERT PCR products pro-
duced for each respective tissue were normalized to α-
tubulin levels and pooled (Table 3, lower right). The
cDNA samples included were limited to those numbered
from A through E, which are all pre-normalized with
respect to cDNA concentration based on the levels of two
housekeeping genes. Compared to lung adjacent tissue,
which had the lowest level of hTERT products, a 14-fold
increase was observed in lung tumour tissue. Colon
tumour and adjacent tissues, on the other hand, had very
similar hTERT levels, about 1.5 to 2-fold higher than in
lung adjacent tissue. In a theoretical perspective, these lev-
els are indicative of hTERT mRNA abundance (all iso-
forms included) in the respective tissues.
Discussion
Regulation of telomerase activity is a complex process
involving transcriptional control, post-translational mod-
ification, positively and negatively acting factors and alter-
native splicing [reviewed in [4,24]]. Telomerase activity in
cells can be measured directly by TRAP analysis [25].
When addressing telomerase expression by other meth-
ods, such as detection of mRNA or protein, caution must
be taken to distinguish between functional and non-func-
tional isoforms. In this respect, detailed knowledge about
the different hTERT isoforms is a prerequisite for proper
experimental set-up and correct interpretation of data. By
screening a number of RT-PCR-generated cDNA clones
from human primary tissues, we identified six novel
hTERT ASPSs and also four out of six previously described
ASPSs. Three novel ASPSs involve alternative splicing of
intron 2 and thus have a dominant relationship to other
ASPSs located further down-stream in the hTERT mRNA.
The ASPSs add to the complexity of telomerase regulation
and should be taken into consideration when interpreting
new and past studies on hTERT expression.
In addition to being a tool for detecting sequence differ-
ences, the panels of cDNA clones may also be used to
address quantitative relationships and mutual correlation
of ASPSs in mRNA isoforms. Since the PCR amplicon used
to generate RT-PCR cDNA clones is rather large, the differ-
ences in size between the different isoforms due to inser-
tions/deletions becomes comparatively smaller. This may
promote a more equal amplification rate of the different
isoforms being co-amplified in the PCR reaction, com-
pared to PCR covering smaller sub-regions of the hTERT
cDNA. The situation with over-amplification of the dele-
tion ASPS Del-e11 (Table 3) may serve as an example.
Accordingly, Del-e11 was not found among the 134
cDNA clones, which implies that such over-amplification
has not occurred when synthesizing the long fragment
used for cloning. In this respect, statistical analysis of
cDNA clones may represent the most accurate method for
quantification of ASPSs in mRNA. The number of clones
analysed here (Fig. 2) is not sufficient to meet statistical
requirements of sample size. Sampling errors are therefore
unavoidable. As seen in the screening of cDNA samples
with primer pairs covering smaller sub-regions of hTERT
(Table 3), several ASPSs were detected in tissues for which
there are no corresponding RT-PCR cDNA clones. Thus,
many ASPSs appear to be more widely expressed than
identified by analysis of clones. The variation in ASPS con-
tent observed between cDNA clones and cDNA samples is
most likely related to a generally low abundance of hTERT
mRNA. Some uncertainty also exist regarding the two
cDNA clones that contained an unspliced intron 14 (Ins-
i14). It is possible that these clones have originated from
nuclear mRNA in which intron 14 is retained because of
incomplete processing.
A useful consequence of mapping individual cDNA clones
is the information obtained on correlation, i.e. the degree
by which the different ASPSs tend to occur together in the
same mRNAs. This information is necessary for predicting
which protein isoforms may be produced in cells since the
majority of ASPSs result in frame shift and premature ter-
mination of translation (Fig. 1B), which will mask other
features located further down-stream in the same mRNA.
The RT-PCR cDNA clones were generated from poly(A)+
mRNA and it is reasonable to assume that the correspond-
ing mRNA isoforms are processed by the translation
machinery with similar efficiency as the normal full-
length isoform. If not, specific mechanisms must exist that
can recognize the different internal insertions/deletions inPage 7 of 10
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the expected frequency of a particular protein isoform
(frame shift, insertion or deletion of aa) depends in part
on the frequency of the corresponding ASPS in mRNA,
but also on the presence of additional ASPSs located fur-
ther upstream. Since the majority of hTERT transcripts in
lung and colon tissues contained two or more ASPSs,
ASPSs located downstream (and in particular 3' to exon 8)
are rarely continuous with the ORF (Fig. 2). Instead, the
pool of hTERT protein in human lung and colon tissues
seems to be dominated by truncated isoforms correspond-
ing to the ASPSs Ins-i2 [1–349], Ins-i2 [?–5273] and Del-
e7e8.
The correlation analysis (Table 2) defined two groups of
ASPSs with a tendency to occur together in the same
mRNAs, but no pair of ASPSs showed a strict positive cor-
relation. With regard to negative correlation the results
were less conclusive, since some ASPSs occur at a low fre-
quency. However, for the more abundant ASPSs being
present in the same tissue samples (Ins-i2 [?–5273], Ins-i4
[1–38], Del-e6 [1–36], Del-e7e8), any single ASPS were
found both combined with and separate from other
ASPSs in individual cDNA clones, which implies that the
alternative splicing occurring at these sites are more or less
independent events. If no ASPSs are strictly correlated, the
hTERT gene may give rise to as many as 384 different
hTERT mRNA isoforms. Many of these are similar in size
to normal full-length hTERT. Considering the number
and location of in-frame insertion/deletion ASPSs (Fig.
1B) and the combination of these with the other ASPSs,
the 384 mRNA isoforms may give rise to 64 different
hTERT protein isoforms. As explained above, the abun-
dance of the different protein isoforms will vary greatly
according to ASPS frequency and position on the 5' to 3'
axis.
RT-PCR analysis of a sub-region in hTERT containing the
Del-e6 [1–36] and Del-e7e8 deletion splice sites is often
used to estimate telomerase expression, since mRNA lack-
ing this alternative splicing is considered to be normal
full-length. Our data showing that a large percentage of
hTERT mRNA may be alternatively spliced in intron 2
implies that this analysis is insufficient for estimation of
hTERT isoforms. The increased complexity in telomerase
expression necessitates a more detailed analysis of hTERT
isoforms, which can measure both upstream and down-
stream splicing at the single-transcript level. Analysing the
different sub-regions in separate PCRs (Table 3) fails to
detect whether the different ASPSs are present in the same
transcripts or not (correlation), which is required for esti-
mation of normal full-length hTERT. Direct analysis of a
PCR product covering all ASPSs is also problematic, since
many isoforms (different combinations of ASPSs) are sim-
ilar in size to normal full-length. It would require a
method with perfect one-nucleotide resolution for frag-
ments above 2 kbp and an acceptable quantitative read-
out. One solution to these problems is to map long PCR
products (or cDNA clones) covering all ASPSs on individ-
ual basis as shown in Figure 2, which gives a direct meas-
urement of all different isoforms being present.
Conclusion
Previous work addressing identification of hTERT ASPSs
[9,14,15] have focused on cell lines, which normally con-
tain high telomerase activity and a high percentage of nor-
mal full-length hTERT mRNA. In the present study, by
analysing a modest number of RT-PCR-generated cDNA
clones from two different human tissues, six novel ASPSs
were identified of which two represented dominating
hTERT isoforms. A better understanding of hTERT mRNA
processing and its implications for telomerase regulation
will require more studies on human primary tissues,
including those that are low or negative for telomerase
activity. It is also necessary to use methods that do not dis-
criminate between mRNA isoforms based on size, as
opposed to PCR, since ASPSs may involve intronic inser-
tions of considerable length. Detailed knowledge of the
different hTERT isoforms present in human tissues and
the ability to distinguish between them is required to
obtain a proper understanding of telomerase function and
regulation, and may identify hTERT sequences suitable for
targeted cancer immuno therapy.
Methods
Tissue samples and cDNA synthesis
Lung and colon tumour/adjacent tissue matched pair
cDNA samples A-E were obtained from Clontech (Catalog
#: K1433-1, K1434-1). Additional tissue samples were
removed by surgery (The Norwegian Radium Hospital,
Oslo, Norway) and stored in RNAlater (Sigma-Aldrich)
for preservation of RNA. The samples were homogenized
in Trizol Reagent (Invitrogen, Basel, Switzerland) using
the Ultra-Turrax T8 homogenizer (IKA-Werke, Staufen,
Germany) and total RNA was isolated and purified
according to the Trizol Reagent manual. Poly(A)+ mRNA
was isolated and double-selected from total RNA using
the GenoPrep Direct mRNA kit (GenoVision, Oslo, Nor-
way) and cDNA synthesis was performed by using the
StrataScript Reverse Transcriptase (Stratagene, La Jolla,
CA) with oligo(dT) priming as described by the manufac-
turer.
Generation of hTERT RT-PCR cDNA clones
PCR fragments encompassing intron positions 2–15 in
the hTERT gene was produced in two consecutive PCR
reactions using two primers (p1255 and m3652; Table 1)
that hybridize within exon 2 and 16, respectively. The first
PCR was performed using the HotStarTaq kit (Qiagen)
with 10% vol/vol cDNA-synthesis reaction as template,Page 8 of 10
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extension for 6 minutes. The second PCR was run using
the Pfu Turbo kit (Stratagene) with 10% vol/vol of the first
PCR as template and other modifications as described for
the first PCR. The product was then separated in an agar-
ose gel and a segment containing PCR products in the
range 1 to 10 kb was cut out and purified using the Wizard
PCR Preps DNA Purification System (Promega). The PCR
products were digested with EcoR I and Xba I and ligated
between the same sites in the pBluescript SK+ vector (Strat-
agene). Following transfection of E. coli DH10B and
growth on LA-amp, colonies were picked at random for
production of plasmid DNA (Wizard Plus SV Minipreps,
Promega).
Mapping of hTERT RT-PCR cDNA clones
Individual hTERT RT-PCR plasmid clones were screened
for the presence of ASPSs by running PCR with a panel of
6-fam-labelled primer pairs (Table 1) covering different
regions of the hTERT cDNA. The products were analysed
with the MegaBACE 1000 capillary electrophoresis unit
(Amersham Biosciences). Clones that contained inser-
tions and/or deletions compared to normal full-length
hTERT cDNA were sequenced through the relevant region
using the MegaBACE sequencing system (Amersham).
PCR analysis of cDNA samples
cDNA samples were screened for the presence of hTERT
ASPSs by performing two consecutive PCR reactions with
a panel of 6-fam-labelled primer pairs (Table 1) covering
different regions of the hTERT gene. The first PCR was run
using the HotStarTaq kit with 10% vol/vol cDNA-synthe-
sis reaction as template, 35 cycles of PCR, annealing at
58°C and extension for 2 minutes. The second PCR was
run using the Pfu Turbo kit (Stratagene) with 10% vol/vol
of the first PCR as template, 20 cycles of PCR and other
parameters as described for the first PCR. The products
were analysed with the MegaBACE 1000 capillary electro-
phoresis unit.
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